Iovance Biotherapeutics, Inc. IOVA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s additional paid-in capital?
- Iovance Biotherapeutics, Inc. (IOVA) reported additional paid-in capital of $3.56B in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Iovance Biotherapeutics, Inc.'s additional paid-in capital increased by 9.2% year-over-year, from $3.26B to $3.56B.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s additional paid-in capital has grown at a 18.4% compound annual growth rate (CAGR), from $1.49B to $3.46B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.